Transparency: Exceptions

Slides:



Advertisements
Similar presentations
1 1Line Training Capacity Release - Phase II Awards and Recall/Reput.
Advertisements

Electronic Timesheet User Manual
© 2013 Sri U-Thong Limited. All rights reserved. This presentation has been prepared by Sri U-Thong Limited and its holding company (collectively, “Sri.
Drafting and Reviewing Confidentiality Agreements West LegalEdcenter 2012.
Innovations in Structured Products October 25, 2010 An Innovator’s Dilemma?
Works Cardholder Tutorial Initial Login, Transaction Review, & Reports.
Mike Zenker Barclays Capital Research (415) November 12, 2007
Anticipated 2008 Generic Launches JULY 2008 David Harding, API Intelligence, Thomson Reuters Source: FDA, NEWPORT HORIZON PREMIUM TM © THOMSON REUTERS.
Adding Genes This presentation gives a quick overview on how to add Genes to Osprey.
ERA Manager Training December 19, Propriety and Confidential. Do not distribute. 2 ERA Manager Overview In an effort to reduce the need for Providers,
PRODUCTIVITY – THE PICTURE FOR THE UK & THE WEST MIDLANDS SUSTAINING COMPETITIVENESS CONFERENCE – THE BELFRY RHYS HERBERT SENIOR ECONOMIST 6 JULY 2012.
MESSAGING IN THE MEDIA TOP 10 DRUGS BASED ON CREDIBILITY INDEX IN THE LITERATURE JOHN KNAPP, DIRECTOR OF ANALYTICS MAY 2009 Your use of these materials.
End User License Agreement Permission to use and redistribute this Document is granted, provided that (1) the below copyright notice appears in all copies.
Access Online Cardholder Transaction Approval Training 1 Client Logo.
Therapeutic area breakdown of lead projects in development for first launch in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM ©
Paragraph IV Patent Challenges – As of July 1, 2008 JULY 2008 David Harding, API Intelligence, Thomson Reuters Source: FDA, NEWPORT HORIZON PREMIUM TM.
Dunedin Enterprise Investment Trust PLC General Meeting – October 2013, Voting Analysis.
Proportion of biotech-derived active substances in development for first launch 31st December APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Manage Supplier Returns.
Office of Housing Choice Voucher Program Voucher Management System – VMS Version Released October 2011.
Proportion of total R&D expenditure by therapeutic area in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Manage and Disposition Inventory Returns.
Global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output MARCH 2008 SOURCE: CMR INTERNATIONAL.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Inspect Material.
2005/2006 Expenditure on biotech derived entities had remained constant APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
1 Pick and Scan Voyager 9. 2 Copyright Statement All of the information and material inclusive of text, images, logos, product names is either the property.
Number of pharmaceutical patent applications and granted patents for 5 major patent issuing authorities JUNE 2008 SOURCE: DERWENT WORLD PATENTS.
Regulatory approval times between submission and marketing authorization approval APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
Availability of High-Quality API for India, China and Rest of World MARCH 2008 David Harding, API Intelligence, Thomson Reuters Source: NEWPORT HORIZON.
End User License Agreement Permission to use and redistribute this Document is granted, provided that (1) the below copyright notice appears in all copies.
Allocation of R&D expenditure in 2005 between chemical entity and biological or biotech active substances APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
The secure site rendering issue (all navigation crushed together as a list at the top of the page) is a compatibility issue with Internet Explorer only.
ERES 2016: “Solvency II – Optimising regulatory capital required to be held against real estate assets. A Case Study” Charles Ostroumoff 10 th June, 2016.
Copyright © 2012, Oracle and/or its affiliates. All rights reserved. Oracle Proprietary and Confidential. 1.
STOCK OPTIONS MONTHLY REPORT
HRMS At India Infoline 2008.
An Introduction to the Bibliographic Metadata Profile in Alma
Welcome! To the ETS – Create Client Account & Maintenance
technology in retirement savings
Monitoring, Managing & Mitigating Property “Market Risk”
To the ETS – PNG Continuation: Online Training Course
<Insert Picture Here>
BIOLOGY / CHEMISTRY CITATIONS GROWTH
Selecting the right provider
Under-rated assets in an over-priced world
Navigating the Portal 18 December 2017 Version 1.0.
Automation in an XML Authoring Environment
Messaging in the Media TOP 10 AUDIENCES BY THERAPY AREA
Transaction Reporting: Sources
2006 Revenue continued to depend on a relatively small number of products APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
, R&D expenditure showed 6% growth annually
2002–2006 Mid and Other sized companies continued to launch the majority of NMEs APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON.
To the ETS – PNG Continuation: Online Training Course
Proportion of total R&D expenditure on alliances or joint ventures by stage of R&D in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
Transaction Reporting: Exception Handling
Transparency Reporting: Status
% of the projects in development in the leading therapeutic areas were considered to have a novel mode of action APRIL 2007 SOURCE: CMR INTERNATIONAL.
Generate Award Steps Screenshots Purpose:
Copy a Grant Proposal Steps Screenshots Purpose:
To the ETS – PNG Continuation: Online Training Course
Pipeline size of Major companies had grown at a steadier rate than that of smaller companies APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Development time for new molecular entities first launched onto the world market between MARCH 2008 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS.
Cycle times decreased in larger but not smaller, companies
Proportion of total R&D expenditure by function in 2005
FOCUS SFTR Version 01 – Updated in January 2019.
© 2013 Sri U-Thong Limited. All rights reserved
How to raise a fault on Business Zone
Provider Maintenance—Accreditation Module
Presentation transcript:

Transparency: Exceptions 3rd January 2018 Version 1.0

Transparency Reporting: Exceptions Table This guide covers the following aspects of the NEX Regulatory Reporting Portal… Transparency Reporting: Exceptions Table Transparency Reporting: Exceptions by Reason 19 November 2018 Confidential

Transparency Reporting: Exceptions Table As with other tables in the Portal, users may specify multiple criteria in order to filter the results displayed on screen. To filter on Message ID or Client reference, complete values must be entered. When filtering on dates, both the Submitted Start Date and Submitted End Date fields must be complete for results to be returned. If filtering on time, both the hours and seconds should be completed. While it’s possible to search on Time Submitted From and/or Time Submitted To, the corresponding Date Submitted value should also be populated. The Exceptions page is designed to show key information for all outstanding rejections from the APA. The data table provides the core information for exception handling, displaying the principal fields which were submitted by the Client, along with the reason(s) for the validation failure(s). The most recent rejections show at the top of the table. Once all criteria are set, users should click ‘Apply’ to see the results At any search the filters can be cleared using the ‘Reset’ button i ii Hovering over either the Client Reference or Message ID values, users are presented with the option to copy the value to their clipboard for user elsewhere (for example to use in filtering). If there are more than 20 exceptions, users can (i) increase the number of rows per page from 20 to 50 or 100 using the dropdown or (ii) navigate through the pages. 19 November 2018 Confidential

Transparency Reporting: Exceptions by Reason The Exceptions by Reason bar chart provides an overview as to the cause of the most recent 100 exceptions to be flagged by the APA within the last 24 hours, along with the exception reason(s) so trends can be inferred. If no exceptions have been recorded within the last 24 hours, the results will be blank 19 November 2018 Confidential

Thank you Should you have any questions, please contact nrrsupport@nex Thank you Should you have any questions, please contact nrrsupport@nex.com All information contained herein (“Information”) is for informational purposes only, is confidential and is the intellectual property of NEX Group plc and/or one of its group companies (“NEX”). The Information is directed to Eligible Counterparties and Professional Customers only and is not intended for Retail Clients (as each term is defined by the rules of the Financial Conduct Authority ("FCA")) or equivalent in a relevant jurisdiction. This Information is not, and should not be construed as, an offer or solicitation to sell or buy any product, investment, security or any other financial instrument or to participate in any particular trading strategy. The Information is not to be relied upon and is not warranted, either expressly or by implication, as to completeness, timeliness, accuracy, merchantability or fitness for any particular purpose. All representations and warranties are expressly disclaimed. Access to the Information by anyone other than the intended recipient is unauthorised and any disclosure, copying or redistribution is prohibited without NEX’s prior written approval. If you receive this information in error, please immediately delete all copies of it and notify the sender. In no circumstances will NEX be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of, any inability to use, or any inaccuracy in the Information. NEX and the NEX logo are trademarks of the NEX group. Certain NEX group companies are regulated by regulatory authorities. For further regulatory information, please see www.nex.com. ©NEX Group plc 2017